Concepedia

Mark Taylor

MT

22

Publications

1.6K

Citations

16

H-Index

1997

Active since

Affiliations

The University of Sydney(Current)

University College London

University of Colorado Boulder

Joint Institute for Laboratory Astrophysics

Westmead Hospital

Mark Taylor is an author at The University of Sydney specializing in engineering, chemistry, and natural sciences.

ORCID

Top concepts

Publications per year

1997–2024

22

Publications

22

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

David Adams, Ivailo Tournev, Mark Taylor et al. · Amyloid · 2022 · 344 citations · Full text

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Mathew S. Maurer, Parag Kale, Marianna Fontana et al. · New England Journal of Medicine · 2023 · 268 citations · Full text

Rituximab in refractory nephrotic syndrome

Kazumoto Iijima, Koichi Kamei, Denis Geary et al. · Pediatric Nephrology · 2009 · 158 citations

, , +5

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 154 citations · Full text

, , +5

Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Iα inhibit NO-induced cerebral dilation

Wolfgang R. Dostmann, Mark Taylor, Christian K. Nickl et al. · Proceedings of the National Academy of Sciences · 2000 · 151 citations · Full text

Rows per page

1–5 of 22